Roy I, Krishnan S, Kabashin AV, Zavestovskaya IN, Prasad PN. Transforming nuclear medicine with nanoradiopharmaceuticals. ACS Nano. 2022;16:5036–61.

Article  CAS  PubMed  Google Scholar 

Lee DS, Cheon GJ. Nuclear theranostics in Asia: in vivo companion diagnostics. Nucl Med Mol Imaging. 2019;53:1–6.

Article  PubMed  PubMed Central  Google Scholar 

Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirmas N, Jadaan R, Al-Ibraheem A. Peptide receptor radionuclide therapy and the treatment of gastroentero-pancreatic neuroendocrine tumors: current findings and future perspectives. Nucl Med Mol Imaging. 2018;52:190–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mullard A. FDA approves first PSMA-targeted radiopharmaceutical. Nat Rev Drug Discov. 2022;21:327.

PubMed  Google Scholar 

Luining WI, Cysouw MCF, Meijer D, Hendrikse NH, Boellaard R, Vis AN, et al. Targeting PSMA revolutionizes the role of nuclear medicine in diagnosis and treatment of prostate cancer. Cancers (Basel). 2022;14:1169.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: making precision medicine possible. CA Cancer J Clin. 2023; https://doi.org/10.3322/caac.21768.

Ahn BC. Contribution of radionuclide theranostics for managing intractable malignancies. Nucl Med Mol Imaging. 2018;52:168–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baum RP, Singh A, Kulkarni HR, Bernhardt P, Rydén T, Schuchardt C, et al. First-in-humans application of 161Tb: a feasibility study using 161Tb-DOTATOC. J Nucl Med. 2021;62:1391–7.

Article  PubMed  PubMed Central  Google Scholar 

Rosar F, Maus S, Schaefer-Schuler A, Burgard C, Khreish F, Ezziddin S. New horizons in radioligand therapy: 161Tb-PSMA-617 in advanced mCRPC. Clin Nucl Med. 2023; https://doi.org/10.1097/RLU.0000000000004589.

Al-Ibraheem A, Doudeen RM, Juaidi D, Abufara A, Maus S. (161)Tb-PSMA radioligand therapy: first-in-human SPECT/CT imaging. J Nucl Med. 2023; https://doi.org/10.2967/jnumed.122.265291.

National Cancer Institute. NCI common terminology criteria for adverse events (CTCAE) data files and related documents. National Institutes of Health; 2018. https://evs.nci.nih.gov/ftp1/CTCAE/About.html

Google Scholar 

Al-Ibraheem A, Mohamedkhair A. Current status of theranostics in Jordan. Nucl Med Mol Imaging. 2019;53:7–10.

Article  CAS  PubMed  Google Scholar 

Al-Ibraheem A, Abdlkadir A, Albalooshi B, Muhsen H, Haidar M, Omar Y, et al. Theranostics in the Arab World; Achievements & Challenges. Jordan Med J. 2022;56:188–205.

Google Scholar 

Seitzer KE, Seifert R, Kessel K, Roll W, Schlack K, Boegemann M, et al. Lutetium-177 Labelled PSMA targeted therapy in advanced prostate cancer: current status and future perspectives. Cancers (Basel). 2021;13:3715.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1919–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hindié E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C. Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of various sizes: implications for radiopharmaceutical therapy. J Nucl Med. 2016;57:759–64.

Article  PubMed  Google Scholar 

Oh SW, Suh M, Cheon GJ. Current status of PSMA-targeted radioligand therapy in the era of radiopharmaceutical therapy acquiring marketing authorization. Nucl Med Mol Imaging. 2022;56:263–81.

Article  PubMed  Google Scholar 

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804.

Article  CAS  PubMed  Google Scholar 

Bodei L, Herrmann K, Schoder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19:534–50.

Article  CAS  PubMed  Google Scholar 

Gracheva N, Müller C, Talip Z, Heinitz S, Köster U, Zeevaart JR, et al. Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy. EJNMMI Radiopharm Chem. 2019;4:12.

Article  PubMed  PubMed Central  Google Scholar 

Hricak H, Abdel-Wahab M, Atun R, Lette MM, Paez D, Brink JA, et al. Medical imaging and nuclear medicine: a Lancet Oncology Commission. Lancet Oncol. 2021;22:e136–e72.

Article  PubMed  PubMed Central  Google Scholar 

Al-Ibraheem A, Abdlkadir AS, Mohamedkhair A, Mikhail-Lette M, Al-Qudah M, Paez D, et al. Cancer diagnosis in areas of conflict. Front Oncol. 2022;12:1087476.

Article  PubMed  PubMed Central  Google Scholar 

Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129–38.

Article  CAS  PubMed  Google Scholar 

Hooijman EL, Chalashkan Y, Ling SW, Kahyargil FF, Segbers M, Bruchertseifer F, et al. Development of [(225)Ac]Ac-PSMA-I&T for targeted alpha therapy according to GMP guidelines for treatment of mCRPC. Pharmaceutics. 2021;13:715.

Article  CAS  PubMed  PubMed Central  Google Scholar